Hints and tips:
Showing results for Brown v. Takeda Pharmaceuticals America Inc.
Related Special Reports
...It hasn’t been an easy feat in America’s profoundly unequal credit system, Bloomberg writes....
...Gordon Brown, the UK’s former prime minister and now a WHO ambassador for global health financing, told the Financial Times that attendees at the vaccine summit would make “decisions about people who are...
...Chief executive Ethan Brown said last month that the company was aiming to develop fully integrated production facilities to reduce labour and logistics costs....
...Idexx said in October that the animal health market had experienced a “V-shaped recovery”....
...George Brown, economist at Investec, said that from May, “things can only get better”, while Robert Wood, economist at Bank of America, predicted, “the only way is up”....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...Economists say a V-shaped recovery is unlikely. Even then it could be two Vs stuck together – a W, in other words....
...The latest acquisition contributes to a record year for Japanese outbound deals, led by Takeda Pharmaceutical’s £46bn agreement to buy Irish drugmaker Shire in April....
...Others focused on the significance of Takeda’s move for its country’s pharmaceuticals industry....
...The combined value of those deals — which include Takeda Pharmaceutical’s ¥7tn planned takeover of Shire — was around ¥11.7tn....
...Corporate giants including US cable group Comcast, wireless provider T-Mobile and Japan’s pharmaceutical maker Takeda reached for M&A to head off competitive threats and expand their businesses....
...Separately, Japan’s Takeda Pharmaceutical has reached a preliminary agreement to buy Irish drugmaker Shire for about £46bn, a deal that could spark a renewed wave of “big pharma” deals....
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...In the latest sign of how eager boardrooms are sparking a record number of “megadeals”, Japan’s top drugmaker Takeda revealed it was weighing a $40bn takeover of Irish rival Shire....
...Separately, Hikma disclosed on Thursday that it will expand its licensing and distribution pact with Japan’s Takeda Pharmaceuticals that will add new products to its Middle East and North Africa portfolio...
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...The deal makes CRH Europe’s second-largest producer of lime, a product used in the chemicals and pharmaceuticals sectors as well as cement....
...Thomas Sheehan, head of global healthcare at Bank of America Merrill Lynch, said despite the slowdown the fundamentals for dealmaking remained unchanged and activity was bound to pick up again....
...Cancer drug maker Takeda Pharmaceutical, fell 2.6 per cent following Trump’s comments....
..., the pharmaceutical company....
...In Japan, Takeda Pharmaceutical slid 2.7 per cent, Astellas Pharma fell 3.9 per cent and Shionogi sank 3.7 per cent on Thursday morning, while in Australia biotech company CSL Ltd dropped 1.4 per cent and...
...She is also co-chair of Mayer Brown’s committee on diversity and inclusion....
...For GlaxoSmithKline and AstraZeneca — twin pillars of Britain’s pharmaceuticals sector — 2016 promises to be a critical year....
...In a Chapter 11 bankruptcy protection filing on Tuesday at a Delaware court, KaloBios Pharmaceuticals listed both its assets and liabilities in the range of $1m to $10m....
International Edition